Chemistry Department, Valdosta State University, Valdosta, GA, 31698, USA.
Philadelphia College of Osteopathic Medicine, Moultrie, GA, USA.
Adv Exp Med Biol. 2024;1457:45-77. doi: 10.1007/978-3-031-61939-7_3.
The SARS-CoV-2 virus caused the 2019 COVID pandemic by infecting almost eight hundred million people worldwide. Because it was a new viral infection, there were no vaccines or small molecule medications that could prevent or treat the disease. This chapter provides some details for an obscure treatment for COVID-19, that has decades of anti-viral activity data both in vitro and in vivo in the literature. The medicinal molecules are compared to other small molecules that were identified as possible medications for COVID-19. We developed a computational method that ranks small molecules and their ability to penetrate mucus in the lungs of a COVID-19 patient. Our focus is ethanol as a COVID-19 treatment. The results discussed here are based on Lipinski Rules and QSAR computational methods as well as in vitro and in vivo data. These parameters indicate that ethanol should be a strong candidate for future evaluations.
SARS-CoV-2 病毒通过感染全球近 8 亿人引发了 2019 年的 COVID 大流行。由于这是一种新的病毒感染，没有疫苗或小分子药物可以预防或治疗这种疾病。本章为 COVID-19 提供了一种鲜为人知的治疗方法的详细信息，该方法在文献中具有数十年的体外和体内抗病毒活性数据。将这些药用分子与其他被确定为 COVID-19 可能药物的小分子进行了比较。我们开发了一种计算方法，对小分子及其穿透 COVID-19 患者肺部粘液的能力进行了排名。我们关注的是乙醇作为 COVID-19 的治疗方法。这里讨论的结果基于 Lipinski 规则和 QSAR 计算方法以及体外和体内数据。这些参数表明，乙醇应该是未来评估的有力候选者。
